Loomis Sayles & Co. L P lessened its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 687,145 shares of the biopharmaceutical company's stock after selling 20,077 shares during the quarter. Loomis Sayles & Co. L P owned about 0.90% of Xenon Pharmaceuticals worth $26,936,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock valued at $100,506,000 after purchasing an additional 1,507,135 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after buying an additional 905,129 shares during the period. Vestal Point Capital LP grew its holdings in Xenon Pharmaceuticals by 57.1% during the 3rd quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company's stock valued at $32,480,000 after buying an additional 300,000 shares in the last quarter. Jennison Associates LLC boosted its holdings in Xenon Pharmaceuticals by 39.0% in the 4th quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company's stock valued at $31,421,000 after purchasing an additional 224,892 shares during the period. Finally, FMR LLC grew its stake in Xenon Pharmaceuticals by 2.2% in the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock worth $272,349,000 after buying an additional 149,511 shares in the last quarter. 95.45% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price target for the company. Royal Bank of Canada restated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Finally, StockNews.com raised Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $57.38.
Check Out Our Latest Analysis on XENE
Xenon Pharmaceuticals Stock Performance
Shares of Xenon Pharmaceuticals stock traded down $0.72 during trading hours on Tuesday, hitting $32.84. The company's stock had a trading volume of 201,349 shares, compared to its average volume of 394,256. Xenon Pharmaceuticals Inc. has a 12-month low of $32.47 and a 12-month high of $46.00. The company has a market cap of $2.51 billion, a PE ratio of -11.64 and a beta of 1.26. The business has a 50 day moving average price of $37.62 and a two-hundred day moving average price of $39.70.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.05. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Insider Buying and Selling at Xenon Pharmaceuticals
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the transaction, the chief executive officer now owns 31,302 shares in the company, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.52% of the stock is currently owned by insiders.
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
